Skip to content
value.today

La Jolla Pharmaceutical Co.

Total raised
$23 M
2 rounds on record
Latest round
$18 M
Sep 2013
First round on record
Mar 2011
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of La Jolla Pharmaceutical Co.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2013$18 MNo. 2$10 to $50 million

La Jolla Pharmaceutical Co.: Raise no. 2, Sep 2013

Investors in this round

21 investors had bought by the notice of Oct 9, 2013: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for La Jolla Pharmaceutical Co. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: RESTRICTED STOCK AWARDS
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Chester Zygmont, Iii · Executive Officer
  • George Tidmarsh · Executive Officer, Director
  • James Rolke · Executive Officer
  • Ruiz Stacey · Executive Officer
  • Saiid Zarrabian · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Chester Zygmont, Iii, Director of finance. Source: SEC Form D, newest notice filed Oct 9, 2013. Read the notice at the SEC.

equitySEC
Mar 2011$5 MNo. 1$2 to $10 million

La Jolla Pharmaceutical Co.: Raise no. 1, Mar 2011

Investors in this round

9 investors had bought by the notice of Apr 18, 2011: 8 accredited, 1 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for La Jolla Pharmaceutical Co. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $14 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Deirdre Y. Gillespie · Executive Officer, Director
  • Gail A. Sloan · Executive Officer
  • Bertrand C. Liang · Director
  • Robert A. Fildes · Director
  • Stephen M. Martin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gail A. Sloan, Chief financial officer. Source: SEC Form D, newest notice filed Apr 18, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • La Jolla Pharmaceutical Co. chose not to state its revenue in its newest notice of a funding round (Oct 2013).

    SEC Form D · Oct 2013

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2013

That is all the official record says: La Jolla Pharmaceutical Co. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: its website does not allow automated readers.

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in La Jolla Pharmaceutical Co.
InvestorKindAmountRoundRoleSource
Tang Capital Management LLCFund or asset managernot statednot statedHeld Series C-1 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Tang Capital Partners LPFund or asset managernot statednot statedHeld Series C-1 preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 21 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by La Jolla Pharmaceutical Co.
NameRoleNamed in
Chester Zygmont, IiiExecutive officerOct 2013
George TidmarshExecutive officerOct 2013
James RolkeExecutive officerOct 2013
Ruiz StaceyExecutive officerOct 2013
Deirdre Y. GillespieExecutive officerApr 2011
Gail A. SloanExecutive officerApr 2011
George TidmarshDirectorOct 2013
Saiid ZarrabianDirectorOct 2013
Bertrand C. LiangDirectorApr 2011
Deirdre Y. GillespieDirectorApr 2011
Robert A. FildesDirectorApr 2011
Stephen M. MartinDirectorApr 2011

About

Company in San Diego, United States.